BriaCell Therapeutics Corp. Warrant (BCTXZ) 10-Year Financial Performance & Capital Metrics

BCTXZ • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutBriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Show more

Revenue $0
EBITDA -$26M +21.2%
Net Income -$26M -449.2%
EPS (Diluted) 0.00
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -373.16%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-449.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg-734.94%

5Y Avg-101.63%

3Y Avg-174.94%

Latest-

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Jul 2016	Jul 2017	Jul 2018	Jul 2019	Jul 2020	Jul 2021	Jul 2022	Jul 2023	Jul 2024	Jul 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-	-
Operating Expenses+	1.67M	2.58M	3.82M	5.07M	3.94M	6.97M	15.29M	23.27M	33.33M	27.2M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	942.02K	876.16K	1.42M	1.05M	1.5M	4.96M	7.27M	7.94M	6.15M	5.93M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	723.43K	1.71M	2.39M	4M	2.43M	2.02M	8.02M	15.34M	27.18M	21.27M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	1.37K	233	12.97K	15.26K	15K	-3K	1K	-1K	0	0
Operating Income+	0	-2.58M	-3.82M	-5.07M	-3.94M	-6.97M	-15.29M	-23.27M	-33.33M	0
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	1%	-	-0.48%	-0.33%	0.22%	-0.77%	-1.19%	-0.52%	-0.43%	1%
EBITDA+	-1.67M	-2.58M	-3.81M	-5.05M	-3.92M	-6.96M	-15.27M	-23.26M	-33.25M	-26.21M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.16%	-0.55%	-0.47%	-0.33%	0.22%	-0.77%	-1.2%	-0.52%	-0.43%	0.21%
D&A (Non-Cash Add-back)	907	233	12.97K	15.26K	15.26K	15.26K	15.27K	15.27K	83.9K	106.63K
EBIT	-1.67M	-2.58M	-4.14M	-4.69M	-4M	-13.74M	-26.84M	-23.27M	-33.33M	-26.31M
Net Interest Income+	3.63K	5.16K	-3.36K	-15.72K	-29.48K	-75.41K	135.75K	891.21K	288.02K	0
Interest Income	3.63K	5.16K	12.27K	9.77K	0	3.15K	136.73K	891.21K	288.02K	0
Interest Expense	0	0	15.63K	25.49K	29.48K	78.55K	979	0	0	0
Other Income/Expense	-1.7M	-1.99K	-335K	352.2K	-85.1K	-6.84M	-11.55M	2.97M	28.4M	0
Pretax Income+	-1.7M	-2.58M	-4.15M	-4.71M	-4.03M	-13.82M	-26.84M	-20.3M	-4.93M	-26.31M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	0.97%	1%
Net Income+	-1.7M	-2.58M	-4.15M	-4.71M	-4.03M	-13.82M	-26.84M	-20.3M	-4.79M	-26.31M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.37%	-0.52%	-0.61%	-0.13%	0.15%	-2.43%	-0.94%	0.24%	0.76%	-4.49%
Net Income (Continuing)	-1.7M	-2.58M	-4.15M	-4.71M	-4.03M	-13.82M	-26.84M	-20.3M	-4.93M	-26.31M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	-302.52K	-546.79K
EPS (Diluted)+	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EPS Growth %	-	-	-	-	-	-	-	-	-	-
EPS (Basic)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Diluted Shares Outstanding	0	0	0	0	0	0	0	0	0	0
Basic Shares Outstanding	0	0	0	0	0	0	0	0	0	0
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jul 2016	Jul 2017	Jul 2018	Jul 2019	Jul 2020	Jul 2021	Jul 2022	Jul 2023	Jul 2024	Jul 2025
Total Current Assets+	833.35K	1.63M	1.88M	168.53K	261.46K	57.8M	42.35M	26.95M	3.65M	19.93M
Cash & Short-Term Investments	820.6K	1.62M	1.75M	157.03K	21.25K	57.27M	41.04M	21.25M	862.09K	17.87M
Cash Only	131.58K	1.01M	720.26K	157.03K	21.25K	57.27M	41.04M	21.25M	862.09K	10.49M
Short-Term Investments	689.02K	601.76K	1.03M	0	0	0	0	0	0	7.37M
Accounts Receivable	2.67K	5.6K	14.56K	2.82K	22.52K	12.57K	24.1K	717.74K	1.37M	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	2.06M
Total Non-Current Assets+	2.35K	1.91K	407.5K	276.12K	260.87K	245.61K	230.34K	215.07K	2.22M	1.72M
Property, Plant & Equipment	449	0	0	0	0	0	0	0	388.18K	296.82K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1	1	274.73K	276.12K	260.87K	245.61K	230.34K	215.07K	199.8K	184.53K
Long-Term Investments	2	2	2	2	2	2	2	2	418.49K	0
Other Non-Current Assets	1.9K	1.9K	132.76K	0	0	0	0	0	1.21M	1.24M
Total Assets+	835.7K	1.64M	2.28M	444.66K	522.33K	58.04M	42.58M	27.16M	5.87M	21.65M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.35%	0.96%	0.4%	-0.81%	0.17%	110.12%	-0.27%	-0.36%	-0.78%	2.69%
Total Current Liabilities+	48.59K	885.9K	1.34M	1.13M	3.96M	556.79K	941.09K	1.8M	7.46M	3.98M
Accounts Payable	0	0	0	0	0	214.12K	463.28K	1.12M	7.17M	0
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	1.12M	322.53K	249.8K	0	0	0	0	0
Deferred Revenue (Current)	0	506.91K	0	0	0	0	0	0	0	0
Other Current Liabilities	48.59K	379K	219.28K	810.79K	3.71M	0	0	0	0	3.98M
Current Ratio	17.15x	1.84x	1.40x	0.15x	0.07x	103.81x	45.00x	14.96x	0.49x	5.01x
Quick Ratio	17.15x	1.84x	1.40x	0.15x	0.07x	103.81x	45.00x	14.96x	0.49x	5.01x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	155.94K	29.82M	31.31M	29.14M	1.1M	337.67K
Long-Term Debt	0	0	0	0	0	25.99K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	-35.63K	29.79M	31.31M	29.14M	1.1M	337.67K
Total Liabilities	48.59K	885.9K	1.34M	1.13M	4.12M	30.37M	32.25M	30.94M	8.56M	4.32M
Total Debt+	0	0	1.12M	322.53K	249.8K	25.99K	0	0	0	0
Net Debt	-131.58K	-1.01M	400.4K	165.49K	228.55K	-57.24M	-41.04M	-21.25M	-862.09K	-10.49M
Debt / Equity	-	-	1.19x	-	-	0.00x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-244.35x	-198.69x	-133.62x	-88.77x	-15616.96x	-	-	-
Total Equity+	787.11K	750.23K	945.02K	-688.66K	-3.6M	27.67M	10.33M	-3.78M	-2.68M	16.79M
Equity Growth %	-0.32%	-0.05%	0.26%	-1.73%	-4.22%	8.69%	-0.63%	-1.37%	0.29%	7.25%
Book Value per Share	-	-	-	-	-	-	0.67	-0.24	-0.06	15.49
Total Shareholders' Equity	787.11K	750.23K	945.02K	-688.66K	-3.6M	27.67M	10.33M	-3.78M	-2.38M	17.33M
Common Stock	3.44M	5.3M	7.84M	11.11M	12.26M	54.77M	65.59M	69.59M	72.17M	0
Retained Earnings	-4.27M	-6.68M	-9.74M	-14.75M	-18.17M	-29.14M	-60.35M	-80.65M	-85.44M	-111.76M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-23.23K	-57.91K	-80.98K	-101.18K	-138.68K	-138.68K	-138.68K	-138.68K	-138.68K	-138.68K
Minority Interest	0	0	0	0	0	0	0	0	-302.52K	-546.79K

Cash Flow

	Jul 2016	Jul 2017	Jul 2018	Jul 2019	Jul 2020	Jul 2021	Jul 2022	Jul 2023	Jul 2024	Jul 2025
Cash from Operations+	-1.2M	-1.54M	-3.81M	-4.15M	-1.27M	-7.75M	-12.48M	-23.74M	-24.13M	-28.17M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.28%	-0.28%	-1.48%	-0.09%	0.69%	-5.12%	-0.61%	-0.9%	-0.02%	-0.17%
Net Income	-1.7M	-2.58M	-4.15M	-4.71M	-4.02M	-13.82M	-26.84M	-20.3M	-4.93M	-26.56M
Depreciation & Amortization	907	233	12.97K	15.26K	15.26K	15.26K	15.27K	15.27K	83.9K	106.63K
Stock-Based Compensation	496.21K	218.25K	365.49K	49.32K	1.69K	1.97M	3.07M	2.19M	1.8M	776.88K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	21.39K	0	328.55K	-342.36K	70.58K	6.36M	11.66M	-2.12M	-28.14M	-2.5M
Working Capital Changes	-22.03K	830.37K	-358.51K	843.33K	2.67M	-2.28M	-391.29K	-3.53M	7.05M	0
Change in Receivables	24.38K	-2.8K	-9.21K	12.63K	-22.52K	9.94K	-11.53K	5.23K	-732.58K	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	-1.41M	249.16K	660.46K	6.05M	-3.89M
Cash from Investing+	158.78K	120.35K	-453.63K	1.09M	0	0	0	0	-681.8K	-7.65M
Capital Expenditures	0	0	0	0	0	0	0	0	-456.8K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	158.78K	120.35K	0	1.09M	0	0	0	0	0	-330K
Cash from Financing+	801.9K	2.32M	4.06M	2.44M	1.17M	65M	-3.74M	3.95M	4.42M	45.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-174.22K	-119.89K	219.52K	113.96K	0	13.71M	6.43M	1.59K	0	45.45M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.2M	-1.54M	-3.81M	-4.15M	-1.27M	-7.75M	-12.48M	-23.74M	-24.58M	-28.17M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.28%	-0.28%	-1.48%	-0.09%	0.69%	-5.12%	-0.61%	-0.9%	-0.04%	-0.15%
FCF per Share	-	-	-	-	-	-	-0.80	-1.49	-0.51	-25.99
FCF Conversion (FCF/Net Income)	0.71x	0.59x	0.92x	0.88x	0.31x	0.56x	0.47x	1.17x	5.04x	1.07x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-174.29%	-336.18%	-490.08%	-3676.99%	-	-114.78%	-141.26%	-619.74%	-	-373.16%
Return on Invested Capital (ROIC)	-	-989.94%	-529.86%	-924%	-	-	-	-	-	-
Debt / Equity	-	-	1.19x	-	-	0.00x	-	-	-	-
Interest Coverage	-	-	-244.35x	-198.69x	-133.62x	-88.77x	-15616.96x	-	-	-
FCF Conversion	0.71x	0.59x	0.92x	0.88x	0.31x	0.56x	0.47x	1.17x	5.04x	1.07x

Frequently Asked Questions

Growth & Financials

BriaCell Therapeutics Corp. Warrant (BCTXZ) grew revenue by 0.0% over the past year. Growth has been modest.

BriaCell Therapeutics Corp. Warrant (BCTXZ) reported a net loss of $26.3M for fiscal year 2025.

Dividend & Returns

BriaCell Therapeutics Corp. Warrant (BCTXZ) has a return on equity (ROE) of -373.2%. Negative ROE indicates the company is unprofitable.

BriaCell Therapeutics Corp. Warrant (BCTXZ) had negative free cash flow of $28.2M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

BriaCell Therapeutics Corp. Warrant (BCTXZ) 10-Year Financial Performance & Capital Metrics

BCTXZ • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$26M +21.2%
Net Income -$26M -449.2%
EPS (Diluted) 0.00
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -373.16%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-449.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg-734.94%

5Y Avg-101.63%

3Y Avg-174.94%

Latest-

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Jul 2016	Jul 2017	Jul 2018	Jul 2019	Jul 2020	Jul 2021	Jul 2022	Jul 2023	Jul 2024	Jul 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-	-
Operating Expenses+	1.67M	2.58M	3.82M	5.07M	3.94M	6.97M	15.29M	23.27M	33.33M	27.2M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	942.02K	876.16K	1.42M	1.05M	1.5M	4.96M	7.27M	7.94M	6.15M	5.93M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	723.43K	1.71M	2.39M	4M	2.43M	2.02M	8.02M	15.34M	27.18M	21.27M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	1.37K	233	12.97K	15.26K	15K	-3K	1K	-1K	0	0
Operating Income+	0	-2.58M	-3.82M	-5.07M	-3.94M	-6.97M	-15.29M	-23.27M	-33.33M	0
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	1%	-	-0.48%	-0.33%	0.22%	-0.77%	-1.19%	-0.52%	-0.43%	1%
EBITDA+	-1.67M	-2.58M	-3.81M	-5.05M	-3.92M	-6.96M	-15.27M	-23.26M	-33.25M	-26.21M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.16%	-0.55%	-0.47%	-0.33%	0.22%	-0.77%	-1.2%	-0.52%	-0.43%	0.21%
D&A (Non-Cash Add-back)	907	233	12.97K	15.26K	15.26K	15.26K	15.27K	15.27K	83.9K	106.63K
EBIT	-1.67M	-2.58M	-4.14M	-4.69M	-4M	-13.74M	-26.84M	-23.27M	-33.33M	-26.31M
Net Interest Income+	3.63K	5.16K	-3.36K	-15.72K	-29.48K	-75.41K	135.75K	891.21K	288.02K	0
Interest Income	3.63K	5.16K	12.27K	9.77K	0	3.15K	136.73K	891.21K	288.02K	0
Interest Expense	0	0	15.63K	25.49K	29.48K	78.55K	979	0	0	0
Other Income/Expense	-1.7M	-1.99K	-335K	352.2K	-85.1K	-6.84M	-11.55M	2.97M	28.4M	0
Pretax Income+	-1.7M	-2.58M	-4.15M	-4.71M	-4.03M	-13.82M	-26.84M	-20.3M	-4.93M	-26.31M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	0.97%	1%
Net Income+	-1.7M	-2.58M	-4.15M	-4.71M	-4.03M	-13.82M	-26.84M	-20.3M	-4.79M	-26.31M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.37%	-0.52%	-0.61%	-0.13%	0.15%	-2.43%	-0.94%	0.24%	0.76%	-4.49%
Net Income (Continuing)	-1.7M	-2.58M	-4.15M	-4.71M	-4.03M	-13.82M	-26.84M	-20.3M	-4.93M	-26.31M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	-302.52K	-546.79K
EPS (Diluted)+	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EPS Growth %	-	-	-	-	-	-	-	-	-	-
EPS (Basic)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Diluted Shares Outstanding	0	0	0	0	0	0	0	0	0	0
Basic Shares Outstanding	0	0	0	0	0	0	0	0	0	0
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jul 2016	Jul 2017	Jul 2018	Jul 2019	Jul 2020	Jul 2021	Jul 2022	Jul 2023	Jul 2024	Jul 2025
Total Current Assets+	833.35K	1.63M	1.88M	168.53K	261.46K	57.8M	42.35M	26.95M	3.65M	19.93M
Cash & Short-Term Investments	820.6K	1.62M	1.75M	157.03K	21.25K	57.27M	41.04M	21.25M	862.09K	17.87M
Cash Only	131.58K	1.01M	720.26K	157.03K	21.25K	57.27M	41.04M	21.25M	862.09K	10.49M
Short-Term Investments	689.02K	601.76K	1.03M	0	0	0	0	0	0	7.37M
Accounts Receivable	2.67K	5.6K	14.56K	2.82K	22.52K	12.57K	24.1K	717.74K	1.37M	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	2.06M
Total Non-Current Assets+	2.35K	1.91K	407.5K	276.12K	260.87K	245.61K	230.34K	215.07K	2.22M	1.72M
Property, Plant & Equipment	449	0	0	0	0	0	0	0	388.18K	296.82K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1	1	274.73K	276.12K	260.87K	245.61K	230.34K	215.07K	199.8K	184.53K
Long-Term Investments	2	2	2	2	2	2	2	2	418.49K	0
Other Non-Current Assets	1.9K	1.9K	132.76K	0	0	0	0	0	1.21M	1.24M
Total Assets+	835.7K	1.64M	2.28M	444.66K	522.33K	58.04M	42.58M	27.16M	5.87M	21.65M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.35%	0.96%	0.4%	-0.81%	0.17%	110.12%	-0.27%	-0.36%	-0.78%	2.69%
Total Current Liabilities+	48.59K	885.9K	1.34M	1.13M	3.96M	556.79K	941.09K	1.8M	7.46M	3.98M
Accounts Payable	0	0	0	0	0	214.12K	463.28K	1.12M	7.17M	0
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	1.12M	322.53K	249.8K	0	0	0	0	0
Deferred Revenue (Current)	0	506.91K	0	0	0	0	0	0	0	0
Other Current Liabilities	48.59K	379K	219.28K	810.79K	3.71M	0	0	0	0	3.98M
Current Ratio	17.15x	1.84x	1.40x	0.15x	0.07x	103.81x	45.00x	14.96x	0.49x	5.01x
Quick Ratio	17.15x	1.84x	1.40x	0.15x	0.07x	103.81x	45.00x	14.96x	0.49x	5.01x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	155.94K	29.82M	31.31M	29.14M	1.1M	337.67K
Long-Term Debt	0	0	0	0	0	25.99K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	-35.63K	29.79M	31.31M	29.14M	1.1M	337.67K
Total Liabilities	48.59K	885.9K	1.34M	1.13M	4.12M	30.37M	32.25M	30.94M	8.56M	4.32M
Total Debt+	0	0	1.12M	322.53K	249.8K	25.99K	0	0	0	0
Net Debt	-131.58K	-1.01M	400.4K	165.49K	228.55K	-57.24M	-41.04M	-21.25M	-862.09K	-10.49M
Debt / Equity	-	-	1.19x	-	-	0.00x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-244.35x	-198.69x	-133.62x	-88.77x	-15616.96x	-	-	-
Total Equity+	787.11K	750.23K	945.02K	-688.66K	-3.6M	27.67M	10.33M	-3.78M	-2.68M	16.79M
Equity Growth %	-0.32%	-0.05%	0.26%	-1.73%	-4.22%	8.69%	-0.63%	-1.37%	0.29%	7.25%
Book Value per Share	-	-	-	-	-	-	0.67	-0.24	-0.06	15.49
Total Shareholders' Equity	787.11K	750.23K	945.02K	-688.66K	-3.6M	27.67M	10.33M	-3.78M	-2.38M	17.33M
Common Stock	3.44M	5.3M	7.84M	11.11M	12.26M	54.77M	65.59M	69.59M	72.17M	0
Retained Earnings	-4.27M	-6.68M	-9.74M	-14.75M	-18.17M	-29.14M	-60.35M	-80.65M	-85.44M	-111.76M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-23.23K	-57.91K	-80.98K	-101.18K	-138.68K	-138.68K	-138.68K	-138.68K	-138.68K	-138.68K
Minority Interest	0	0	0	0	0	0	0	0	-302.52K	-546.79K

Cash Flow

	Jul 2016	Jul 2017	Jul 2018	Jul 2019	Jul 2020	Jul 2021	Jul 2022	Jul 2023	Jul 2024	Jul 2025
Cash from Operations+	-1.2M	-1.54M	-3.81M	-4.15M	-1.27M	-7.75M	-12.48M	-23.74M	-24.13M	-28.17M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.28%	-0.28%	-1.48%	-0.09%	0.69%	-5.12%	-0.61%	-0.9%	-0.02%	-0.17%
Net Income	-1.7M	-2.58M	-4.15M	-4.71M	-4.02M	-13.82M	-26.84M	-20.3M	-4.93M	-26.56M
Depreciation & Amortization	907	233	12.97K	15.26K	15.26K	15.26K	15.27K	15.27K	83.9K	106.63K
Stock-Based Compensation	496.21K	218.25K	365.49K	49.32K	1.69K	1.97M	3.07M	2.19M	1.8M	776.88K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	21.39K	0	328.55K	-342.36K	70.58K	6.36M	11.66M	-2.12M	-28.14M	-2.5M
Working Capital Changes	-22.03K	830.37K	-358.51K	843.33K	2.67M	-2.28M	-391.29K	-3.53M	7.05M	0
Change in Receivables	24.38K	-2.8K	-9.21K	12.63K	-22.52K	9.94K	-11.53K	5.23K	-732.58K	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	-1.41M	249.16K	660.46K	6.05M	-3.89M
Cash from Investing+	158.78K	120.35K	-453.63K	1.09M	0	0	0	0	-681.8K	-7.65M
Capital Expenditures	0	0	0	0	0	0	0	0	-456.8K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	158.78K	120.35K	0	1.09M	0	0	0	0	0	-330K
Cash from Financing+	801.9K	2.32M	4.06M	2.44M	1.17M	65M	-3.74M	3.95M	4.42M	45.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-174.22K	-119.89K	219.52K	113.96K	0	13.71M	6.43M	1.59K	0	45.45M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.2M	-1.54M	-3.81M	-4.15M	-1.27M	-7.75M	-12.48M	-23.74M	-24.58M	-28.17M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.28%	-0.28%	-1.48%	-0.09%	0.69%	-5.12%	-0.61%	-0.9%	-0.04%	-0.15%
FCF per Share	-	-	-	-	-	-	-0.80	-1.49	-0.51	-25.99
FCF Conversion (FCF/Net Income)	0.71x	0.59x	0.92x	0.88x	0.31x	0.56x	0.47x	1.17x	5.04x	1.07x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-174.29%	-336.18%	-490.08%	-3676.99%	-	-114.78%	-141.26%	-619.74%	-	-373.16%
Return on Invested Capital (ROIC)	-	-989.94%	-529.86%	-924%	-	-	-	-	-	-
Debt / Equity	-	-	1.19x	-	-	0.00x	-	-	-	-
Interest Coverage	-	-	-244.35x	-198.69x	-133.62x	-88.77x	-15616.96x	-	-	-
FCF Conversion	0.71x	0.59x	0.92x	0.88x	0.31x	0.56x	0.47x	1.17x	5.04x	1.07x

Frequently Asked Questions

Growth & Financials

BriaCell Therapeutics Corp. Warrant (BCTXZ) grew revenue by 0.0% over the past year. Growth has been modest.

BriaCell Therapeutics Corp. Warrant (BCTXZ) reported a net loss of $26.3M for fiscal year 2025.

Dividend & Returns

BriaCell Therapeutics Corp. Warrant (BCTXZ) has a return on equity (ROE) of -373.2%. Negative ROE indicates the company is unprofitable.

BriaCell Therapeutics Corp. Warrant (BCTXZ) had negative free cash flow of $28.2M in fiscal year 2025, likely due to heavy capital investments.